Christina Chiang focuses her practice on merger and acquisition, PRC investment, securities investment, energy law, real estate/infrastructure and general corporate.
Christina regularly advises clients with cross-border mergers and acquisitions, including Amazon's subscription of Alchip's private placement shares (2024), National Resilience's strategic alliance with Taiwan Bio-Manufacturing Corp. (2024), Celltrion's sale of APAC primary care assets (2024), Carrier's sale of CCR, fire and security businesses (2024), Novartis' spin-off of Sandoz business (2023), Bora Pharmaceuticals' acquisition of TWi Pharmaceuticals (2022 MAPECT M&A Awards - Deal of the Year), Celltrion's acquisition of primary care assets (2020), KKR's acquisition of LCY Group (IFLR Asia-Pacific Awards 2020-PE Deal of the Year), Toshiba Memory's (Kioxia) acquisition of Lite-on's SSD business (2020 MAPECT M&A Awards-Deal of the Year) and MBK Partners' disposal of CNS Group. Christina also advised on various de-SPAC transactions, including the listing on the NASDAQ of FST Corp. (KBSX) (2025), Semilux International Ltd. (SELX) (2024) and Gorilla Technology Group Inc (GRRR) (2022).
Christina also advises clients on energy projects in Taiwan (including wind farms and solar projects) and complex real estate and infrastructure transactions, including DDSP's and Kepple's development of an 80MW greenfield data center in Taiwan (2024).
學歷
MS in International Business, National Chengchi University (2007)
LL.B., National Chengchi University (2005)
專業領域
Mergers and Acquisitions; PRC Investment; Securities investment; Energy Law; Real Estate/Infrastructure; General Corporate
